Market Size in 2022 | Market Forecast in 2030 | CAGR (in %) | Base Year |
---|---|---|---|
USD 5 Billion | USD 8.3 Billion | 4.5% | 2022 |
The global cardiac arrest treatment market size was evaluated at $5 billion in 2022 and is slated to hit $8.3 billion by the end of 2030 with a CAGR of nearly 4.5% between 2023 and 2030.
Cardiac arrest is a situation wherein the heart stops beating suddenly. This occurs when the demand for oxygen towards the heart does not meet the requirement and results in the mortality of heart muscle cells causing a heart attack. Besides, there are several other reasons causing cardiac arrest like cardiomyopathy, coronary artery disease, Brugada syndrome, and long QT syndrome. Among these, coronary artery disease is the most common cause of sudden cardiac arrest especially among people above 35 years age group. The Brugada syndrome and long QT syndrome cause abnormal heart rate which develops a cardiac arrest problem within the body. The cardiomyopathy situation causes the heart muscle to develop to an abnormal size and causes cardiac arrest problems.
Surge in heart ailments to boost the expansion of the global market over 2023-2030
Increase in cardiovascular disorders caused due to sedentary & inactive lifestyles with sitting jobs will boost the global cardiac arrest treatment market trends. For instance, as per the research study published in 2021, the most common heart disorder witnessed in the patients is atrial fibrillation which is a major risk factor causing ischemic stroke. This has resulted in huge morbidity in patients and incurred a high economic burden on the healthcare sector of various emerging economies, thereby increasing the demand for treating cardiovascular disorders. An increase in the aging populace and a surge in investments in R&D associated with heart diseases are the major factors driving the expansion of the global market. Increase in research on treating cardiac arrests will further enlarge the scope of the growth of the global market. New drug launches will further increase the global market demand. For instance, in the first half of 2022, Rapid Response Revival Research Limited, a key Australian firm, produced CellAED in the UK.
Massive treatment charges for heart ailments will put brakes on the global industry
High costs of treating heart disorders and less availability of healthcare experts in emerging economies will put brakes on the global cardiac arrest treatment industry surge.
Supportive government reimbursement policies can create new growth avenues for the global market
Favorable government compensation policies will open new growth opportunities for the global cardiac arrest treatment market in the years ahead.
High drug costs can create huge challenges in the growth path of the global industry
Huge costs of medicines and strict laws pertaining to the approval of cardiac equipment will restrict the growth of the cardiac arrest treatment industry across the globe.
The global cardiac arrest treatment market is sectored into treatment, distribution channel, and region.
In treatment terms, the global cardiac arrest treatment market is segregated drugs and medical devices segments. Furthermore, the medical devices segment, which accumulated nearly half of the global market revenue share in 2022, is anticipated to register the highest CAGR in the upcoming years. The growth of the segment in the assessment timeline can be owing to the growing use of defibrillators for restoring the normal heartbeat as it can send electric impulses to the heart. Moreover, these medical devices are utilized for preventing arrhythmia.
Based on the distribution channel, the cardiac arrest treatment industry across the globe is divided into hospitals, pharmacies, and others segments. Moreover, the hospitals segment, which accumulated nearly 47% of the global industry revenue share in 2022, is projected to lead the distribution channel segment in the upcoming years. The growth of the segment in the assessment timeline can be due to a rise in the number of surgeries performed in hospitals & clinics that results in huge demand for medical equipment in hospitals.
Report Attributes | Report Details |
---|---|
Report Name | Cardiac Arrest Treatment Market |
Market Size in 2022 | USD 5 Billion |
Market Forecast in 2030 | USD 8.3 Billion |
Growth Rate | CAGR of 4.5% |
Number of Pages | 228 |
Key Companies Covered | Pfizer Inc., GE Healthcare, Novartis AG, Bayer AG, Boston Scientific Corporation, Amgen Inc., Abbott Laboratories, and others. |
Segments Covered | By Treatment, By Distribution Channel, and By Region |
Regions Covered | North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA) |
Base Year | 2022 |
Historical Year | 2017 to 2021 |
Forecast Year | 2023 - 2030 |
Customization Scope | Avail customized purchase options to meet your exact research needs. Request For Customization |
North America is projected to maintain global market dominance over the assessment timeline
North America, which contributed about 45% of the global cardiac arrest treatment market revenue in 2022, is predicted to lead the global market revenue in the ensuing years. The growth of the market in the region can be attributed to the rise in the rate of heart ailments witnessed in the adult population and the aging population in countries such as the U.S. and Canada. Presence of key players in these countries will drive the expansion of the market in the region.
Asia-Pacific cardiac arrest treatment industry is set to register the fastest CAGR in the upcoming years owing to a rise in the cases of heart disorders in densely populated countries such as India and China. Apart from this, a prominent rise in the use of medicines and medical equipment used for treating cardiac ailments will further embellish the growth of the market in the sub-continent.
The global cardiac arrest treatment market profiles key players such as:
By Treatment
By Distribution Channel
FrequentlyAsked Questions
Cardiac arrest is a situation wherein the heart stops beating suddenly. This occurs when the demand for oxygen towards the heart does not meet the requirement and results in the mortality of heart muscle cells causing a heart attack.
The global cardiac arrest treatment market growth can be owing to surge in the heart ailments.
According to a study, the global cardiac arrest treatment industry size was $5 billion in 2022 and is projected to reach $8.3 billion by the end of 2030.
The global cardiac arrest treatment market is anticipated to record a CAGR of nearly 4.5% from 2023 to 2030.
The Asia-Pacific cardiac arrest treatment industry is set to register the highest CAGR over the forecasting timeline owing to a rise in the cases of heart disorders in densely populated countries such as India and China. Apart from this, a prominent rise in the use of medicines and medical equipment used for treating cardiac ailments will further embellish the growth of the market in the sub-continent.
The global cardiac arrest treatment market is led by players such as Pfizer Inc., GE Healthcare, Novartis AG, Bayer AG, Boston Scientific Corporation, Amgen Inc., and Abbott Laboratories.
The cardiac arrest treatment market report covers the geographical market along with a comprehensive competitive landscape analysis. It also includes cash flow analysis, profit ratio analysis, market basket analysis, market attractiveness analysis, sentiment analysis, PESTEL analysis, trend analysis, SWOT analysis, trade area analysis, demand & supply analysis, Porter’s five force analysis, and value chain analysis.
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed